Abstract
Parkinsons disease (PD) is a neurodegenerative disorder of central nervous system (CNS) that impaired the patient motor skills, speech and other functions. Adenosine A2A receptors have a unique cellular distribution in the neuron, which is used as a potential target for PD. Homology modeling was used to construct the 3-D structure of A2A using the known template (PDB: 2VT4), and the stereochemical quality was validated. Several effective antagonist drugs were selected and active amino acid residues in A2A were targeted on the basis of robust binding affinity between proteindrug interactions in molecular docking. Six antagonists, Bromocriptine, Cabergoline, Etilevodopa, Lysuride, Melevodopa and Pramipexole, were found more potent for binding and the active amino acids residues were identified (http://www.rcsb.org/pdb/) in A2A receptor. It could be used as the basis for rationale designing of novel antagonist drugs against Parkinsons diseas.
Keywords: Adenosine A2A, Parkinson's disease, antagonists, homology modeling, docking
Current Aging Science
Title: Homology Modeling of Adenosine A2A Receptor and Molecular Docking for Exploration of Appropriate Potent Antagonists for Treatment of Parkinsons Disease
Volume: 2 Issue: 2
Author(s): Vijai Singh and Pallavi Somvanshi
Affiliation:
Keywords: Adenosine A2A, Parkinson's disease, antagonists, homology modeling, docking
Abstract: Parkinsons disease (PD) is a neurodegenerative disorder of central nervous system (CNS) that impaired the patient motor skills, speech and other functions. Adenosine A2A receptors have a unique cellular distribution in the neuron, which is used as a potential target for PD. Homology modeling was used to construct the 3-D structure of A2A using the known template (PDB: 2VT4), and the stereochemical quality was validated. Several effective antagonist drugs were selected and active amino acid residues in A2A were targeted on the basis of robust binding affinity between proteindrug interactions in molecular docking. Six antagonists, Bromocriptine, Cabergoline, Etilevodopa, Lysuride, Melevodopa and Pramipexole, were found more potent for binding and the active amino acids residues were identified (http://www.rcsb.org/pdb/) in A2A receptor. It could be used as the basis for rationale designing of novel antagonist drugs against Parkinsons diseas.
Export Options
About this article
Cite this article as:
Singh Vijai and Somvanshi Pallavi, Homology Modeling of Adenosine A2A Receptor and Molecular Docking for Exploration of Appropriate Potent Antagonists for Treatment of Parkinsons Disease, Current Aging Science 2009; 2 (2) . https://dx.doi.org/10.2174/1874609810902020127
DOI https://dx.doi.org/10.2174/1874609810902020127 |
Print ISSN 1874-6098 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-6128 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Delivering RNA Interference to the Mammalian Brain
Current Gene Therapy Novel Therapeutic Strategies for Dementia
CNS & Neurological Disorders - Drug Targets Flavonoids in Human Health: From Structure to Biological Activity
Current Nutrition & Food Science Involvement of Immune Response in the Pathogenesis of Amyotrophic Lateral Sclerosis: A Therapeutic Opportunity?
CNS & Neurological Disorders - Drug Targets Targeting Generation of Antibodies Specific to Conformational Epitopes of Amyloid β-Derived Neurotoxins
CNS & Neurological Disorders - Drug Targets Insights into the Design of p97-targeting Small Molecules from Structural Studies on p97 Functional Mechanism
Current Medicinal Chemistry Endocannabinoid System: Emerging Role from Neurodevelopment to Neurodegeneration
Mini-Reviews in Medicinal Chemistry Biphasic Mechanisms of Neurovascular Unit Injury and Protection in CNS Diseases
CNS & Neurological Disorders - Drug Targets Aquaporins and Neurodegenerative Diseases
Current Neuropharmacology High Throughput Screening for Neurodegeneration and Complex Disease Phenotypes
Combinatorial Chemistry & High Throughput Screening Oxidative Status in Multiple Sclerosis and Off-Targets of Antioxidants: The Case of Edaravone
Current Medicinal Chemistry Nicotinamide as a Foundation for Treating Neurodegenerative Disease and Metabolic Disorders
Current Neurovascular Research Therapeutic Options in Prevention and Treatment of Aspartoacylase Gene Mutation Resulting Abnormalities in Canavan Disease
Current Pharmacogenomics Physiological and Pathological Functions of Acid-Sensing Ion Channels in the Central Nervous System
Current Drug Targets Biochemical Markers in CSF of ALS Patients
Current Medicinal Chemistry Inflammation in the CNS: Understanding Various Aspects of the Pathogenesis of Alzheimer's Disease
Current Alzheimer Research tPA in the Central Nervous System: Relations Between tPA and Cell Surface LRPs
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) On 11C Chemistry Reviews - Surveying and Filling the Gaps
Current Organic Chemistry Collateral Damage: Contribution of Peripheral Inflammation to Neurodegenerative Diseases
Current Topics in Medicinal Chemistry Pharmacoperones: A New Therapeutic Approach for Diseases Caused By Misfolded G Protein-Coupled Receptors
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued)